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Abstract
Background: Ovarian carcinoma is a rarely curable disease, for which new treatment options are required. As agents 
that block HMG-CoA reductase and the mevalonate pathway, the statin family of drugs are used in the treatment of 
hypercholesterolemia and have been shown to trigger apoptosis in a tumor-specific manner. Recent clinical trials show 
that the addition of statins to traditional chemotherapeutic strategies can increase efficacy of targeting statin-sensitive 
tumors. Our goal was to assess statin-induced apoptosis of ovarian cancer cells, either alone or in combination with 
chemotherapeutics, and then determine these mechanisms of action.
Methods: The effect of lovastatin on ovarian cancer cell lines was evaluated alone and in combination with cisplatin 
and doxorubicin using several assays (MTT, TUNEL, fixed PI, PARP cleavage) and synergy determined by evaluating the 
combination index. The mechanisms of action were evaluated using functional, molecular, and pharmacologic 
approaches.
Results: We demonstrate that lovastatin induces apoptosis of ovarian cancer cells in a p53-independent manner and 
synergizes with doxorubicin, a chemotherapeutic agent used to treat recurrent cases of ovarian cancer. Lovastatin 
drives ovarian tumor cell death by two mechanisms: first, by blocking HMG-CoA reductase activity, and second, by 
sensitizing multi-drug resistant cells to doxorubicin by a novel mevalonate-independent mechanism. This inhibition of 
drug transport, likely through inhibition of P-glycoprotein, potentiates both DNA damage and tumor cell apoptosis.
Conclusions: The results of this research provide pre-clinical data to warrant further evaluation of statins as potential 
anti-cancer agents to treat ovarian carcinoma. Many statins are inexpensive, off-patent generic drugs that are 
immediately available for use as anti-cancer agents. We provide evidence that lovastatin triggers apoptosis of ovarian 
cancer cells as a single agent by a mevalonate-dependent mechanism. Moreover, we also show lovastatin synergizes 
with doxorubicin, an agent administered for recurrent disease. This synergy occurs by a novel mevalonate-
independent mechanism that antagonizes drug resistance, likely by inhibiting P-glycoprotein. These data raise 
important issues that may impact how statins can best be included in chemotherapy regimens.
Background
As a malignancy with particularly poor prognosis, novel
therapeutic options are urgently required for the treat-
ment of ovarian cancer[1,2] In 2009, approximately
25,000 women will be diagnosed in North America and
most will die of their disease, making it the fifth leading
cause of cancer mortality in women[3] The majority of
ovarian cancer cases present as advanced stage III or IV
disease and treatment usually involves surgical cytore-
duction, followed by adjuvant platinum/taxane chemo-
therapy, with about 70-80% response rates. While
patients typically undergo a period of remission of 1-2
years, more than half eventually relapse. Some patients
with recurrent disease become refractory to platinum
treatment. They are generally next treated with regimens
of gemcitabine, topotecan, and/or liposomal doxorubicin,
but with very limited success[4,5] The reduced rate of
response in these patients is typically due to the develop-
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Page 2 of 13ment of drug resistance[6] Taken together, to directly
increase the quality and longevity of life, new and imme-
diate therapeutic approaches are urgently required to
combat ovarian cancer.
We and others have shown that the statin family of
drugs exhibit antiproliferative activity against cancer cells
without causing collateral damage to normal cells[7]. Sta-
tins inhibit the rate-limiting enzyme of the mevalonate
(MVA) pathway, HMG-CoA reductase (HMGCR), and
have been used for decades as safe and effective agents in
the control of hypercholesterolemia[7,8] In addition to
cholesterol, the MVA pathway gives rise to a number of
crucial biochemical end-products, including ubiquinone,
dolichol, isopentenyladenine, and isoprenoid precursors.
Statins can trigger tumor cells to undergo a classic cas-
pase-dependent, apoptotic response that is reversible by
exogenous addition of MVA or the isoprenoid precursors,
geranylgeranyl pyrophosphate (GGPP) and farnesyl pyro-
phosphate (FPP)[7]. Thus, the statin family of drugs are
immediately available for use as part of the arsenal of
molecular targeted therapeutics to combat cancer.
Like most anti-cancer agents, statins demonstrate
robust efficacy on some but not all tumor-types, empha-
sizing the importance of matching the agent with the sen-
sitive, responsive cancer. Statins have been extensively
shown to trigger apoptosis of cell lines derived from hae-
matological malignancies, including acute myelogenous
leukemia and multiple myeloma[7,9]. This preclinical
data has been recently translated to Phase I/II clinical tri-
als that have shown promising results when statins have
been used in combination with standard chemother-
apy[10,11] Similarly, median survival was doubled with
the addition of statins to 5-fluorouracil in advanced hepa-
tocellular carcinomas[12] As was recently reviewed, solid
tumor derived cell lines that have recently been shown to
be statin sensitive include breast, colorectal, lung, pros-
tate, and pancreatic, [13]. however, preclinical work
focusing on ovarian cancer is required to determine
whether statins have the potential to be used to combat
this tumor type as well. Very recently, preliminary reports
have indicated that ovarian carcinoma is sensitive to sta-
tin-induced apoptosis, providing a unique alternative to
treating this deadly disease[14,15].
To advance these findings, we demonstrate that lovas-
tatin induces apoptosis of ovarian cancer cells in a p53-
independent manner and synergizes with doxorubicin, a
chemotherapeutic agent used to treat recurrent ovarian
cancer. Lovastatin triggers ovarian tumor cells to undergo
apoptosis by two mechanisms: first, by blocking HMGCR
activity; and second, by increasing the level of doxorubi-
cin within drug-resistant cells. Together, these data sup-
port further pre-clinical and clinical evaluations of statins




Cells were grown as a monolayer in RPMI 1640 medium
with 10% fetal bovine serum in a humidified incubator at
37°C in 5% CO2. Ectopic expression of the ecotropic
receptor was conducted as described[16]. and subsequent
gene transfer was achieved by infection with retrovirus
produced using the Phoenix ecotropic packaging system
as previously described[17] A2780 cells were generated to
ectopically express either a p53DD construct or the
empty YFP vector control by flow sorting for stably
expressing cells[17] Cells were also generated and
selected to ectopically express Bcl-2 and its correspond-
ing empty vector control.
MTT assays
The MTT assays were conducted as previously
described[18]. except 3750 cells/well of a 96-well plate
were plated and after 24 hours, cells were exposed to
lovastatin (5 to 100 μM; activated as previously
described[19]) for 48 hours followed by MTT tetrazolium
substrate for 2 hours.
Immunoblotting
Cells were seeded in 100 mm dishes for 24 hours. Treat-
ments of 20 μM lovastatin or vehicle control were com-
pleted for 24 or 48 hours before cells were harvested for
PARP (Cell Signaling Technology), Rap1 (Santa Cruz Bio-
technology), p53 (Santa Cruz Biotechnology), actin
(Sigma-Aldrich), and tubulin (Calbiochem) immunoblot-
ting as described[9,17] Lysates from cells exposed to 8 GY
of radiation for 8 hours were immunoblotted for p21
(Santa Cruz Biotechnology) and tubulin. Lysates from
A2780 pBP, A2780 Bcl-2, A2780ADR GFP and
A2780ADR Bcl-2 were immunoblotted for Bcl-2 and
tubulin.
Fixed PI
Cells were seeded in 100 mm dishes for 24 hours and
exposed to indicated lovastatin concentrations or vehicle
control for indicated times (24, 48, or 72 hours), washed
in PBS, fixed in 70% ethanol, stained with 50 μg/mL PI
(Sigma-Aldrich) and analyzed by a FACScalibur flow
cytometer (BD Bioscience). Ten thousand events were
scored and analysis was performed using Cell Quest soft-
ware (BD Bioscience) to assess the dying, pre-G1 popula-
tion.
Synergy experiments
Cells were plated for MTT assays and treated for 24 hours
with concentration ranges of lovastatin and either doxo-
rubicin or cisplatin that are centered on each drug's
MTT50 (A2780ADR - 20, 14, and 42 μM, respectively;
A2780 - 10, 4, 50 μM, respectively; A2780CIS - 30, 5, 112
μM, respectively). CEMVBL cells were similarly plated
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tered on each drug's MTT50 (42 and 68 μM, respectively).
Drug treatments were performed individually or in fixed
ratio combinations (at 4×, 2×, 1×, 1/2×, 1/4×, 1/8×
MTT50 values) as described previously[20]. Combination
index (CI) plots were generated using CalcuSyn software
(Ver 2; Biosoft) based on algorithms developed by Chou
and Talalay[21] to determine whether the drugs synergize
(CI < 1).
Measurement of P-gp expression
As previously described, [22] 1 × 106 cells were harvested,
washed in 1 mL buffer (1xPBS, 0.5%BSA), resuspended in
1 mL staining buffer (1xPBS, 0.5%BSA, 0.1%NaN3) with
or without 20 μL of FITC-labelled anti-human P-gp (BD
Pharmigen), and incubated on ice for 40 minutes in the
dark. Cells were washed with staining buffer, resus-
pended in 1 mL buffer, and fluorescence in the FL1 chan-
nel was detected by flow cytometry. 10 000 events were
captured for analysis with Cell Quest software.
Measurement of intracellular doxorubicin
Intracellular doxorubicin was measured as described pre-
viously[23]. with some alterations. Briefly, for accumula-
tion experiments, 2 × 105 A2780ADR cells were seeded in
6-well plates for 24 hours and treated. Alternatively, 5 ×
105 CEMVBL cells were seeded and treated in 6-well
plates. A2780ADR cells were exposed to 7 μM doxorubi-
cin (half MTT50) alone or in combination with 5, 10 or 20
μM lovastatin for 3 hours. An additional sample was
treated with doxorubicin, 10 μM lovastatin, and 100 μM
MVA as well. CEMVBL cells were exposed to 34 μM dox-
orubicin (half MTT50) alone or in combination with 2.63,
5.25, 10.5 or 21 μM lovastatin for 3 hours. An additional
sample was treated with doxorubicin, 21 μM lovastatin,
and 100 μM MVA as well. For retention experiments,
A2780ADR cells were incubated with a combination of 7
μM doxorubicin and 10 μM lovastatin as above and were
further incubated for two hours in doxorubicin-free
media with or without 10 μM lovastatin. For both accu-
mulation and retention experiments, after treatment,
cells were washed twice in cold phosphate buffered saline
(PBS), resuspended in 1 mL of cold PBS, and filtered for
single cells on ice. Intracellular doxorubicin fluorescence
was measured by detecting the natural fluorescence of
doxorubicin with flow cytometry (FL2 channel); 10,000
events were scored.
Comet assay
A2780ADR cells were seeded in 100 mm plates for 24
hours and exposed to either a control, 10 μM lovastatin, 7
μM doxorubicin, or both 10 μM lovastatin and 7 μM dox-
orubicin together for 24 hours. Comet assays were per-
formed as described previously[24] Briefly, comets were
visualized by fluorescence microscopy (Axioskop micro-
scope, Zeiss) and images were analyzed using Komet 5.5
software (Kinetic Imaging). DNA damage was quantified
from the analysis of 75 comets per treatment/experiment
using the olive tail moment [Tail moment = (%DNA) ×
(distance traveled)].
TUNEL assay
TUNEL and PI dual-staining was carried out as per man-
ufacturer's instructions (APO-BRDU kit; Phoenix Flow
systems Inc.). Briefly, 2 million cells were seeded in 100
mm plates for 24 hours and treated with the indicated
drugs for 24 hours to determine both the proportion of
TUNEL-positive cells and the cell cycle phase from which
apoptotic cells arose.
Results
Human ovarian carcinoma cells are sensitive to lovastatin-
induced apoptosis
To evaluate the sensitivity of human ovarian cancer cells
to the anti-proliferative activity of statins, a panel of ten
ovarian cancer cell lines was exposed to increasing con-
centrations of lovastatin for 48 hours. Lovastatin was the
statin used in this study because it is readily available as a
generic drug and is lipophilic, a feature of statins that
have shown efficacy in recent breast cancer stud-
ies[25,26] MTT assays showed that lovastatin exposure
triggered a substantial decrease in activity in all cell lines
with MTT50 values that ranged from approximately 2 to
40 μM (Figure 1A).
To further define the antiproliferative effect of lovasta-
tin, we next used two independent methods to evaluate
whether lovastatin triggered apoptosis in the cell line
panel. We first assessed the population of pre-G1 cells by
fixed PI flow cytometry in response to 20 μM lovastatin
for 48 hours. This fixed dose was used in all cell lines to
be able to compare relative sensitivity. In all ten cell lines
tested, an increase in the pre-G1 population was mea-
sured (Figure 1B, histograms, and data not shown). As an
independent assay for apoptosis we assessed whether the
cleavage of poly ADP-ribose polymerase (PARP) was
detectable in cells treated with either lovastatin or vehicle
control for 48 hours. Cleaved PARP was observed in all
cell lines, except DOV13 (Figure 1B, inset western blots,
and data not shown). Thus, ovarian cancer cells undergo
apoptosis in response to lovastatin exposure.
Treating cells with 20 μM lovastatin for 48 hours elic-
ited a robust apoptotic response from which a potent
MVA-dependent rescue would be required. Cells were
co-treated with lovastatin and either 100 μM MVA, 10
μM GGPP, or 10 μM FPP to determine if lovastatin-
induced apoptosis in ovarian cancer cells is MVA-depen-
dent. MVA reversed the effect of lovastatin and both
GGPP and FPP were also able to partially rescue cells
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lovastatin-induced apoptosis in ovarian cancer cells is
therefore dependent upon HMGCR inhibition.
To ensure that the MVA pathway block was due to
lovastatin we evaluated the prenylation status of Rap1, a
protein that is known to be exclusively geranylgeranylated
(Figure 1C). Immunoblot analysis showed accumulation
of the unprocessed form of Rap1 in all cell lines exposed
to lovastatin for 24 hours, indicating that drug uptake was
universally achieved.
Lovastatin triggers apoptosis of human ovarian carcinoma 
cells in a time and dose dependent manner
Novel treatment options for women diagnosed with ovar-
ian cancer are sorely needed. Our data suggests that sta-
tins have potential to be used as chemotherapeutics for
these patients but it is important to determine whether
they are effective at therapeutically achievable (low
micromolar) concentrations. As a representative sensitive
ovarian cancer cell line, A2780 cells were exposed to
increasing concentrations of lovastatin (1, 5, 10, and 20
Figure 1 Lovastatin triggers apoptosis in human ovarian cancer cell lines. A series of experiments were conducted to define the cytotoxic effects 
of lovastatin on a panel of human ovarian cancer cell lines. A: Cells were exposed to a range of lovastatin concentrations for 48 hours to determine 
MTT50 values by MTT assay. MTT50s are presented as the mean of 2-4 independent experiments with error bars representing standard deviation. B: Cells 
were exposed to 20 μM lovastatin or vehicle control for 24 or 48 hours to assess the presence of PARP cleavage by western blotting. Tubulin was 
probed as a loading control. Experiments were conducted 2-3 times and representative blots are shown (see inset). For fixed PI, cells were seeded and 
treated as above to 20 μM lovastatin or vehicle control. Results are normalized to the ethanol controls (= 1%) and data are presented as the mean of 
2-4 independent experiments with error bars representing standard deviation. C: Cells were seeded as above, exposed to 20 μM lovastatin or a vehicle 
control for 24 hours, lysed and immunoblotted to detect processed (P) and unprocessed (U) Rap1 and actin. Experiments were conducted 2-3 times 
and representative blots are shown.
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fixed PI analysis and the population of pre-G1 cells mea-
sured (Figure 2). Consistent with previous studies in
AML, [11,27-30] the results clearly demonstrate that
lovastatin-induced apoptosis of these cells is both dose-
and time-dependent, and that the 20 μM, 24 hour lovas-
tatin treatment commonly used in the laboratory is not
significantly different (p = 0.49) from clinically achievable
doses of lovastatin for 72 hours.
Lovastatin-induced apoptosis of human ovarian carcinoma 
cells is p53-independent
To identify molecular features of cancers that predict sen-
sitivity, we evaluated the role of the tumor suppressor p53
in lovastatin-induced apoptosis of ovarian cancer cells.
Taking a molecular approach, a dominant negative p53
truncation, p53DD, was ectopically expressed in A2780
cells (Figure 3A). These cells are known to harbor endog-
enous wildtype p53 [31]. The activity of p53 in these cells
was evaluated by exposing them to 8 GY of gamma-irra-
diation measuring p53-dependent induction of the
cyclin-dependent kinase inhibitor, p21. As expected, p21
was induced after irradiation of parental and empty vec-
tor-expressing cells, but this induction was substantially
decreased in A2780-p53DD cells (Figure 3B).
As a positive control for the inhibition of lovastatin-
induced apoptosis, A2780 cells ectopically expressing
Bcl-2 or the corresponding empty vector were also ana-
lyzed (Figure 3C). Fixed PI was used to measure the pre-
G1 population of cells treated with 20 μM lovastatin for
24 hours (Figure 3D). Empty vector controls and cells
expressing p53DD underwent a similar degree of apopto-
sis while ectopic expression of Bcl-2 significantly
decreased the amount of lovastatin-induced apoptosis by
50%, demonstrating the p53-independence of lovastatin-
induced apoptosis in human ovarian cancer cells.
Lovastatin synergizes with doxorubicin in P-gp expressing 
cells
As statins will likely be used in cancer treatment as part
of drug cocktails, we next evaluated whether the addition
of lovastatin to agents presently used in chemotherapy
regimes of ovarian cancer would increase efficacy. Cispla-
tin and doxorubicin were selected as representative
agents used in the treatment of primary and relapsed
drug-resistant ovarian cancer. To model primary onset
disease A2780 cells were treated in combination with cis-
platin and lovastatin. To model relapsed disease
A2780ADR cells, a multi-drug resistant cell line derived
from parental A2780 cells, were treated with lovastatin in
combination with either cisplatin or doxorubicin. Syn-
ergy experiments were adapted from the methods
described by Chou and Talaly [21] to determine the anti-
proliferative effect of drug combinations with lovastatin.
In A2780ADR cells, lovastatin and cisplatin were additive
(C = 1) when combined at higher concentrations (Figure
4A, white bars). By contrast, lovastatin significantly syn-
ergized with doxorubicin in drug-resistant A2780ADR
cells (CI < 1; Figure 4A, black bars).
A commonly proposed mechanism of multi-drug resis-
tance (MDR) in recurrent ovarian cancer is elevated drug
efflux, which is often due to increased activity of the
ATP-binding cassette (ABC) transporter ABCB1 (previ-
ously named MDR1) gene that encodes P-glycoprotein
(P-gp)[4] A2780ADR cells, previously developed by cul-
turing parental A2780 cells in the presence of doxorubi-
cin, have gained resistance to the drug by overexpressing
P-gp, [22] which we confirmed by flow cytometry with a
fluorescence-tagged antibody to P-gp (Figure 4C, left).
Figure 2 Lovastatin-induced apoptosis of ovarian cancer cells occurs at therapeutically achievable levels. A2780 cells were exposed to a 
range of lovastatin concentrations or vehicle control for 24, 48, or 72 hours to demonstrate the dose- and time- dependence of lovastatin-induced 
apoptosis as measured by fixed PI analysis. Results are normalized to each vehicle control (= 1%) and are presented as the mean of 3 independent 
experiments with error bars representing standard deviation. Dashed line highlights equivalence between doses of 20 μM for 24 hours and 5 μM for 
72 hours. *, p < 0.05 compared to the untreated controls by a Student's t-Test.
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MTT assay in A2780ADR cells (4.9 μM at 48 hours; 3.1 to
7.7 95% CI) was approximately 100 times higher than in
A2780 cells (0.04 μM at 48 hours; 0.03 to 0.06 95% CI).
We hypothesized that P-gp mediated efflux of doxorubi-
cin, a known substrate of P-gp, was being blocked by
lovastatin via an unknown mechanism. To verify that
synergy between lovastatin and doxorubicin was not sim-
ply an artifact of the A2780ADR cell system, we employed
an alternative paired parental and MDR model derived
Figure 3 Lovastatin-induced apoptosis in ovarian cancer cells is p53-independent. A: A2780 YFP and A2780 p53DD cells were harvested, lysed, 
and immunoblotted with anti-p53 antibody to detect p53DD and with anti-tubulin as a loading control. B: A2780 YFP and p53DD cell were seeded 
and then exposed to 8 GY of radiation for 8 hours, harvested, lysed, and immunoblotted for the detection of p21 and tubulin. C: A2780 pBP and Bcl-
2 cells were seeded as above, harvested, lysed, and immunoblotted with antibodies to Bcl-2 and tubulin. All experiments were conducted 2-3 times 
and representative blots are shown. D: A2780 YFP, p53DD, pBP, and Bcl-2 cells were seeded as above and exposed to 20 μM lovastatin or a control for 
48 hours and analyzed by fixed PI to measure the pre-G1 population. Pre-G1 populations are expressed as ratios (lovastatin pre-G1/ethanol pre-G1) 
and normalized to the YFP vector control (= 1). Data are presented as the mean of 6 independent experiments with error bars representing standard 
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Page 7 of 13from acute lymphoblastic leukemia, CEM and CEMVBL
cells, respectively. We also confirmed that the CEMVBL
cells both overexpress P-gp on their cell surface and have
a significantly higher MTT50 for doxorubicin when com-
pared to the parental CEM cells (Figure 4C, right, and
data not shown). Interestingly, lovastatin synergized sig-
nificantly with doxorubicin in CEMVBL cells (Figure 4B)
using the same experimental design as above. We also
determined that lovastatin did not synergize with cispla-
tin in either parental A2780 cells (Additional file 1: Sup-
plemental Figure S1A) or the drug-resistant A2780CIS
cells (Additional file 1: Supplemental Figure S1B), both of
which had little to no P-gp expression compared to
A2780ADR cells (Additional file 1: Supplemental Figure
S1C). Furthermore, lovastatin and doxorubicin were bor-
derline synergistic or additive in A2780 and A2780CIS
(Additional file 1: Supplemental Figure S1) cells treated in
a similar manner.
Lovastatin increases doxorubicin retention in P-gp 
expressing cells
To elucidate the molecular mechanisms underlying this
synergy we formulated a working model in which lovasta-
tin blocks P-gp, thereby inhibiting its ability to drive the
efflux of doxorubicin from MDR cells. As the fluores-
cence of doxorubicin can be directly measured by flow
cytometry, we evaluated the amount of doxorubicin
within A2780ADR and CEMVBL cells exposed to a sub-
lethal dose of doxorubicin alone or in combination with
increasing concentrations of lovastatin. Notably,
A2780ADR (Figure 5A) and CEMVBL (Figure 5B) cells
exposed to a combination of lovastatin and doxorubicin
contained more intracellular doxorubicin than cells
treated with doxorubicin alone. This process was dose-
dependent, as increasing concentrations of lovastatin led
to an increase in the accumulation of intracellular doxo-
rubicin, but also observed at low physiologically relevant
concentrations of both lovastatin (Figure 5A; 5B) and
doxorubicin (data not shown).
Lovastatin also appears to prevent the active efflux of
doxorubicin (Figure 5C). In this experiment, cells were
treated with lovastatin and doxorubicin together to "load"
the cells with doxorubicin. To determine differential
degrees of doxorubicin retention, cells were further incu-
bated for 2 hours in doxorubicin-free media with or with-
out lovastatin. Remarkably, incubation with lovastatin
resulted in more intracellular doxorubicin remaining
after 2 hours. Partial loss of doxorubicin observed in cells
that were incubated with lovastatin is likely due to passive
diffusion or efflux mediated by alternative mechanisms
because this same pattern was observed in parental
A2780 cells, which do not overexpress P-gp, treated in the
same manner (data not shown). These data suggest that
lovastatin may inhibit P-gp from actively pumping doxo-
rubicin out of the cell. Surprisingly, lovastatin-induced
accumulation of doxorubicin was not reversed by co-
incubation with MVA (Figure 5A; B), suggesting that a
mechanism independent of HMGCR inhibition is at
Figure 4 Lovastatin synergizes with doxorubicin in P-gp expressing ovarian cancer cells. A2780ADR (A) and CEMVBL (B) cells were plated for 
MTT assays and treated for 24 hours with concentration ranges of lovastatin and either doxorubicin or cisplatin. Combination index (CI) plots were 
generated using CalcuSyn software to determine whether the drugs synergize (CI < 1). Data is presented as the mean of 5-10 independently deter-
mined CI values with error bars representing standard deviation. *, p < 0.05 compared to additivity (CI = 1) by a Single Sample t-Test. C: Substantially 
higher P-gp expression was detected by flow cytometry in A2780ADR and CEMVBL cells compared to A2780 and CEM cells, respectively, using a flu-
orescence-tagged anti-P-gp antibody. The experiment was conducted 3 times; a representative histogram is shown.
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lovastatin and chemotherapeutics that are substrates of
P-gp to increase efficacy of tumor cell death.
Combining lovastatin and doxorubicin potentiates DNA 
damage and apoptosis in P-gp expressing cells
To further explore the mechanisms synergy between
lovastatin and doxorubicin, we next measured DNA dam-
age, commonly induced by doxorubicin, by comet assay.
Drug concentrations used in this set of experiments were
relatively sub-lethal, half-MTT50 values to minimize the
effect of each drug on its own. Although these doses are
higher than physiologically achievable levels, they remain
experimentally tractable. While doxorubicin exposure
alone resulted in a slight, significant increase in DNA
damage compared to either control- or lovastatin-treated
cells, combined treatment with both lovastatin and doxo-
rubicin together resulted in a statistically significant 3-
fold increase in DNA damage over doxorubicin alone
(Figure 6A).
We next determined whether lovastatin could also
potentiate doxorubicin-induced apoptosis. For these
experiments we used dual-staining of TUNEL and fixed
PI to measure the degree of apoptosis and determine if
cells undergo apoptosis preferentially from any particular
phase of the cell cycle. A2780ADR cells were treated as
before and analyzed by flow cytometry. Similar to the
comet assays, doxorubicin alone induced a small increase
in apoptosis compared to either the control- or lovasta-
tin-treated cells (Figure 6B). Cells treated with lovastatin
alone, however, showed no evidence of either DNA dam-
age or apoptosis. This is expected due to the low, sub-
lethal dose used. Conversely, cells exposed to the combi-
nation of lovastatin and doxorubicin underwent a statisti-
cally significant 10-fold increase in apoptosis when
compared to doxorubicin alone. While over-expression of
Bcl-2 did not inhibit the combined activity of lovastatin
and doxorubicin (Additional file 2: Supplemental Figure
S2), apoptotic cells were detected from all phases of the
cell cycle (Figure 6C). Therefore, doxorubicin and lovas-
tatin combine synergistically to induce high levels of both
DNA damage and apoptosis in human ovarian cancer
cells.
Discussion
Our work provides important evidence to support fur-
ther pre-clinical and clinical evaluation of the statin fam-
ily of drugs as anticancer agents against ovarian cancer.
Figure 5 Lovastatin increases doxorubicin retention in P-gp expressing ovarian cancer cells. A2780ADR (A) and CEMVBL (B) cells were treated 
with lovastatin and doxorubicin as indicated for 3 hours, with or without MVA. Intracellular doxorubicin fluorescence was measured by flow cytometry 
and the results are normalized to cells treated with doxorubicin alone (= 100%). Data are presented as the mean of 3-4 independent experiments with 
error bars representing standard deviation. Dashed line highlights the lack of reversal by MVA. *, p < 0.05 compared to the 100% control by a Student's 
t-Test. C: A2780ADR cells were incubated with a combination of 7 μM doxorubicin and 10 μM lovastatin for 3 hours and were further incubated for 
two hours in doxorubicin-free media, with or without 10 μM lovastatin. Intracellular doxorubicin was determined by flow cytometry and the results 
are normalized to cells co-treated with doxorubicin and lovastatin without further incubation (= 100%). Data are presented as the mean of 3 indepen-
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Page 9 of 13We show that a panel of ovarian cancer derived cell lines
is sensitive to lovastatin-induced apoptosis, consistent
with recent reports[14,15]. Mechanistically this apoptotic
pathway is functionally blocked by exogenous MVA or
the isoprenoid precursors GGPP and FPP. Moreover, we
show that statin killing occurs irrespective of the muta-
tional status of the tumor suppressor p53. Our results
using a dominant negative p53 clearly indicate that lovas-
tatin-induced apoptosis is substantially p53-independent
and this is also supported by the observation that p53-
null SKOV3 cells are able to undergo lovastatin-induced
apoptosis. These observations are particularly important
for ovarian cancer in which p53 mutation rates have been
estimated between 23 and 79%[32]. We also show that
lovastatin can synergize with doxorubicin and potentiate
apoptosis. Synergy is achieved by lovastatin blocking
drug efflux through a MVA-independent mechanism that
enables the intracellular retention and genotoxic action of
Figure 6 Lovastatin potentiates DNA damage and apoptosis induced by doxorubicin. A2780ADR cells were exposed to either a control, 10 μM 
lovastatin, 7 μM doxorubicin, or both 10 μM lovastatin and 7 μM doxorubicin together. A: Comet assays were performed and the olive tail moment 
determined for 75 cells of each condition. Data are presented as the mean of 4 independent experiments with error bars representing standard de-
viation. *, p < 0.05 compared to the untreated control by a Student's t-Test. TUNEL and PI dual-staining was carried out to determine the proportion 
of TUNEL-positive cells and if apoptotic cells originated predominantly in any particular phase of the cell cycle. B: Data are presented as the mean of 
3 independent experiments measuring either TUNEL positivity (left) or PreG1 population (right) with error bars representing standard deviation. *, p 
< 0.05 compared to the untreated control by a Student's t-Test. C: Representative dot plots comparing the degree of TUNEL staining to DNA content. 
D: Schematic model illustrating two independent mechanisms of statin activity and the manner in which they can be combined to maximize clinical 
efficacy.
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Page 10 of 13doxorubicin. To the best of our knowledge, these latter
features of statin-induced apoptosis have not yet been
reported for ovarian cancer. Exploiting the unique ability
of statins to drive apoptosis by the mevalonate-depen-
dent mechanism alone warrants further evaluation of
these agents in the treatment of ovarian cancer (Figure
6D, left side). In addition, using statins, like lovastatin, to
synergize with chemotherapeutics that are P-gp sub-
strates (Figure 6D, right side) may be a feature of lovasta-
tin action that further maximizes ovarian cancer cell
death and improves patient survival.
It is interesting to note that while several reports have
shown that P-gp expressing cells were more sensitive sta-
tin-induced apoptosis, [33-36] our results show the oppo-
site trend (Figure 1A). Indeed, the MTT50 results for
lovastatin in A2780ADR and A2780CIS cells are roughly
5-fold higher than in the parental A2780 cells. The reason
for this difference is unknown, but it is possible that the
drug resistant cells have exploited additional mechanisms
of resistance, such as increasing the expression of anti-
apoptotic proteins.
As agents approved for use in humans, the MVA-
dependent antiproliferative activity of statins has
prompted several Phase I clinical trials of statins on a
wide variety of late-stage cancers, and although statins
were well tolerated, only limited responses were evident.
More recently statins have been evaluated on cohorts of
patients harboring a tumor-type that has been shown to
be sensitive to statin-induced apoptosis in tissue culture
studies. In these focused, tumor-specific, hypothesis-
driven trials, statins have demonstrated some efficacy as a
single agent[29,30,37] but more wide-reaching effects
were evident when statins were combined with chemo-
therapeutics [10,11,38,39]. Thus, our data identifying
ovarian carcinoma as a statin-sensitive tumor type
strongly supports the evaluation of statins in strategies to
combat this disease.
A recent, retrospective epidemiological study showed
that statin use in patients diagnosed with epithelial ovar-
ian cancer is associated with improved survival[40].
Although only a relatively small number of patients met
the criteria for the study, multivariable analysis identified
statin use as an independent positive prognostic factor
after controlling for age, stage, grade, and suboptimal
cytoreduction, providing clinical support for the use sta-
tin-based combinations in cancer treatment. Similar
recent analyses of breast cancer also provided additional
insights. For example, it appears that lipophilic statin use
after breast cancer diagnosis has been associated with
decreased risk of recurrence[25,26]. Overall, these recent
studies provide supporting rationale for the use of statins
as anticancer agents and suggest that lipophilic statins
(lovastatin, simvastatin, atorvastatin, fluvastatin, and
pitavastatin) may be more effective, perhaps because they
are better able to penetrate solid tumors compared to
hydrophilic statins. From a pharmacological perspective,
the lipophilic statins that demonstrate higher plasma
concentrations with longer retention times in the circula-
tion include atorvastatin and fluvastatin. This suggests
these lipophilic agents may best target the tumor and
show higher anti-cancer efficacy in vivo, consistent with a
previous study comparing lipophilic and hydrophilic sta-
tins in ovarian cancer[15].
Recent evidence suggests that there may be a connec-
tion between drug resistance and regulation of the MVA
pathway. In MDR AML cells, HMGCR mRNA levels were
not significantly elevated upon statin exposure in cells
that showed preferential sensitivity to lovastatin[36].
More recently, it was suggested that high levels of
HMGCR mRNA correlates with sensitivity to statin-
induced apoptosis[15]. It will be interesting in the future
to determine how HMGCR expression impacts statin
sensitivity and whether it can be exploited as a biomarker.
Mechanistically, it is clear that statins target HMG-CoA
reductase and similarly trigger tumor cells to undergo
apoptosis[7]. (Figure 6D, left side), however, several prac-
tical questions remain unresolved regarding statins as
potential P-gp inhibitors (Figure 6D, right side). This new
role of statins would be particularly important to con-
sider in the management of ovarian cancer as survival
and disease recurrence after taxane/carboplatin treat-
ment has recently been associated with specific P-gp
polymorphisms[41]. Several classes of specific P-gp
inhibitors have been developed but have unfortunately
shown general cytotoxicity in clinical trials[42]. This is
thought to be due to targeting P-gp not only on tumor
cells, but also on several normal vital organs that consti-
tutively express P-gp. It would be easy to assume that sta-
tins blocking P-gp will similarly cause general
cytotoxicity, however, it is not known whether statins and
classic P-gp inhibitors are mechanistically or functionally
similar. Lovastatin has been reported to inhibit P-gp in a
limited number of biochemical studies with two very dis-
tinct caveats: none have used human cells overexpressing
drug-selected human P-gp and the concentrations of
drug used have been well beyond the physiologically
achievable range [43-46]. Moreover, the results of these
studies have been in conflict when using either the acid or
lactone form of the statin[45,46]. Importantly, we con-
ducted our work with physiologically attainable concen-
trations of both doxorubicin and lovastatin in human cell
systems selected to overexpress human P-gp.
It is also worth noting that Bcl-2 was unable to inhibit
cell death induced by the combination of lovastatin and
doxorubicin (Additional file 2: Supplemental Figure S2).
While the reasons for this result are unclear, it is possible
that the cells have become drug-resistant through means
other than the MDR machinery, such as upregulation of
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Page 11 of 13one or more anti-apoptotic proteins, and thereby ren-
dered forced expression of Bcl-2 incapable of rescuing
cells further. Further study will be required to better
understand the interplay of all mechanisms of drug resis-
tance.
Statins ultimately need to advance to clinical trials
where their inhibition of drug efflux can be monitored on
both tumor and normal cells. Interestingly, other groups
have reported that lovastatin protects normal cells from
doxorubicin-induced cytotoxicity [47-49] which, when
combined with our data, suggests that statins may affect
P-gp differently in normal cells compared to tumor cells.
It is entirely possible that lovastatin functionally blocks P-
gp in a manner that is distinct from classic P-gp inhibi-
tion. Evidence that statins can be successfully combined
with various P-gp substrates is also established from their
safe and effective combination in the polypharmacy of
cardiac patients with hypercholesterolemia[50]. Taken
together, our results suggest the ability of statins to trig-
ger apoptosis of ovarian cancer cells may be exploited in
the treatment of this disease, and that the potential P-gp
inhibitory properties of certain statins, like lovastatin,
warrant further investigation. It is also of interest to note
that at MTT50 concentrations, but not higher, lovastatin
had a slightly antagonistic relationship with cisplatin, a
non-P-gp substrate (Figure 4A, Additional file 1: Supple-
mental Figure S1). This observation suggests that it could
potentially be deleterious to combine lovastatin with cis-
platin in the treatment of some patients. Furthermore,
lovastatin and doxorubicin were also able to synergize in
A2780 parental and A2780CIS cells. While this suggests
that elements other than P-gp are involved in the interac-
tion between these two drugs, the degree of synergy
observed in A2780ADR cells is higher, indicating that
inhibition of P-gp is likely an important mechanism of
how lovastatin synergizes with doxorubicin. These results
require further investigation to truly understand the
manner by which lovastatin functionally interacts with
other chemotherapeutics.
Determining which statin will maximally target differ-
ent tumors, including ovarian, under different conditions
will also be vital to advancing patient care. In the 14 com-
pleted and 20 or more ongoing clinical trials evaluating
statins in the prevention or treatment of cancer, [10-
12,30,37-39,51-57] the rationale for choosing a particular
statin is not presented and appears random. Indeed, the
ideal choice of statin as an anti-cancer agent remains
unclear, however, evidence suggests lipophilic agents with
pharmacologic properties that favor access to solid
tumors is of high priority. Further work is required to bet-
ter understand the activity of these statins as potential
inhibitors of P-gp and to determine if this inhibition is
specific to tumor cells in vivo.
Conclusions
Overall, our results identify ovarian cancer cells as sensi-
tive to statin-induced apoptosis and strongly suggest that
statins can play a role in the treatment of ovarian carci-
noma. As approved agents, statins can make immediate
impact either as additions to traditional inductive ther-
apy, as maintenance therapy to secure lasting remissions,
or as salvage treatment for terminal, refractory disease.
Our results may impact ongoing clinical trials using sta-
tins as anti-cancer agents and will be important to con-
sider in the design of future clinical trials targeting
various tumor types, including ovarian cancer.
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